Recommended

Sarepta’s DMD drug Elevidys issued FDA label update
Rare disease gene therapy granted European first approval
Johnson & Johnson agrees $3bn oncology acquisition
European Commission grants EU first for J&J’s Simponi biosimilar
Researchers validate approach that supports animal-based pyrogen test replacement
ON DEMAND webinar: automating QC testing for radiopharmaceutical production
Insmed secures EU approval for Brinsupri (brensocatib)
Moderna invests over $140m to onshore mRNA medicine manufacturing in US
news

Boehringer Ingelheim to advance bacterial cancer therapeutics

1
SHARES

Through a new acquisition, Boehringer Ingelheim will have rights to a platform that enables the design of immuno-oncology combination therapies in one single agent.

Boehringer Ingelheim to advance bacterial cancer therapeutics - immuno-oncology

Credit: nitpicker / Shutterstock.com

Boehringer Ingelheim is acquiring Swiss biotech T3 Pharmaceuticals AG (T3 Pharma), for up to £406 million (450 million CHF), boosting its immuno-oncology portfolio.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The pharmaceutical company will utilise T3 Pharmaceutical’s proprietary bacterial cancer therapy platform that consisting that delivers immune-modulating bioactive proteins to cancer cells and tumour micro-environments. Overall, the process enables the design of immuno-oncology combination therapies in one single agent.

Although immunotherapies have provided significant advancement in the cancer treatment landscape, long-term remissions only occur in 15-20 percent of these patients, according to Boehringer Ingelheim.

Advancing immuno-oncology therapies to ensure patient benefit

Boehringer Ingelheim’s strategy

Boehringer Ingelheim aims to boost these remission rates by harnessing immuno-oncology platforms such as T-Cell Engagers (TcEs), oncolytic viruses, and cancer vaccines, which have the potential to extend the benefits of immunotherapy to more patients.

“The acquisition of T3 Pharma will significantly expand our immuno-oncology pipeline portfolio and is synergistic with many of our existing R&D programs. This will bring us closer to achieving our vision of driving a paradigm shift in cancer care treatments,” stated Michel Pairet, Member of the Board of Managing Directors at Boehringer Ingelheim with responsibility for the Innovation Unit.

T3 Pharma is “very excited to continue and accelerate the successful development of our bacterial delivery platform as part of Boehringer Ingelheim,” declared the company’s CEO, Simon Ittig.

The immuno-oncology therapeutic market

In analysis published by GlobalData in July 2023, immuno-oncology therapies have emerged as a novel treatment category. There were a “record number of immuno-oncology approvals” in 2022, with 10 new innovative drugs being approved. If this trend continues, immuno-oncology therapies could make up a greater share of the types of oncology therapies reaching the market, Quentin Horgan, Associate Director at GlobalData stated. However, Horgan added that it is important to note: “only three [immuno-oncology] therapies [were] approved in the first half of 2023.”

Share via
Share via